Kornimate/medical-research-clean huggingface dataset:
a study of jincaopian tablets on chronic pelvic pain after pelvic inflammatory disease

Conditions: Chronic Pelvic Pain

Summary: the objective of this phase iii trial to evaluate the efficacy and safety of jincaopian tablets in the treatment of subjects with chronic pelvic pain after pelvic inflammatory disease

chronic pelvic pain is the major sequela of pelvic inflammatory disease and it's a common, burdensome, and costly condition that disproportionately affects women. this multicenter, randomized, double-blind, dose-parallel, placebo-controlled phase iii clinical trial is designed to evaluate the efficacy and safety of jincaopian tablets in the treatment of subjects with chronic pelvic pain after pelvic inflammatory disease. in this trial, 414 subjects were enrolled and randomized to either "jincaopian tablets" group, or the "placebo" group in a 2:1 ratio. the treatment period is 12 weeks and the follow-up period is 4 weeks.

Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria for chronic pelvic pain sequelae of pelvic inflammatory disease; * the average vas score of pain in the week before enrollment is ≥4; * the mccormack scale of physical signs at the time of enrollment is 4 to 12 points (including 4 points and 12 points); * women aged 18 to 50 (including 18 and 50) with a history of sexual life; * voluntarily participate in this clinical trial, give informed consent and sign the informed consent form. exclusion criteria: * pelvic inflammatory disease (acute attack); * pregnant or lactating women, women of childbearing age who are unwilling to take effective measures to prevent pregnancy during the trial and within 6 months after the trial; * previously diagnosed with cervical intraepithelial neoplasia, primary/secondary dysmenorrhea, pelvic stasis syndrome and chronic pelvic pain caused by other non-pelvic inflammatory diseases; * complicated with specific vaginitis such as vulvovaginal candidiasis, trichomonas vaginitis, bacterial vaginosis; * gynecological tumors (maximum diameter of uterine fibroids greater than 3cm and submucosal fibroids), endometriosis, adenomyosis, acute cervicitis, tuberculous pelvic inflammatory disease, interstitial cystitis and other diseases related symptoms; * placement of intrauterine device in the past 3 months; absence of uterus and bilateral appendages; * received related treatment or took drugs with similar functions and indications within 14 days before the introduction; * liver function: alt or ast\>1.5 times the upper limit of normal value；renal function：scr\>1.0 times the upper limit of normal value; * serum ca125 and erythrocyte sedimentation \> 1.1 times the upper limit of normal value. * combined with serious cardiovascular, cerebrovascular, hematopoietic system and other serious diseases; * have an allergic history to the experimental drug; * have a long history of alcoholism or drug abuse; * intellectual disabilities or mental disorders; * participated in other clinical trials within the past 3 months; * the investigator believes that it is not suitable to participate in this clinical trial.
squalamine for the treatment in proliferative diabetic retinopathy

Conditions: Retinal Neovascularization

Summary: the purpose of this study is to determine the efficacy in the use of topical squalamine lactate ophthalmic solution, 0.2% in the treatment of retinal neovascularization resulting from proliferative diabetic retinopathy.


Eligibility criteria:
inclusion criteria: * age \>= 18 years * individuals \<18 years old are not being included because pdr is so rare in this age group that the diagnosis of pdr may be questionable. * diagnosis of diabetes mellitus (type 1 or type 2) * any one of the following will be considered to be sufficient evidence that diabetes is present: * current regular use of insulin for the treatment of diabetes * current regular use of oral anti-hyperglycemia agents for the treatment of diabetes * documented diabetes by ada and/or who criteria (see procedures manual for definitions) * at least one eye meets the study eye criteria * able and willing provide informed consent exclusion criteria: * significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant. * a condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control). * individuals in poor glycemic control who, within the last 4 months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next 4 months should not be enrolled. * participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval for the indication being studied. * note: study participants cannot receive another investigational drug while participating in the study. * known allergy to any component of the study drug. * blood pressure \> 180/110 (systolic above 180 or diastolic above 110). * if blood pressure is brought below 180/110 by anti-hypertensive treatment, individual can become eligible. * myocardial infarction, other acute cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 4 months prior to randomization. * systemic anti-vegf or pro-vegf treatment within 4 months prior to randomization. * these drugs should not be used during the study. * for women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 3 years. * women who are potential study participants should be questioned about the potential for pregnancy. investigator judgment is used to determine when a pregnancy test is needed. * individual is expecting to move out of the area of the clinical center during the study. * history of allergy to squalamine

Keywords: proliferative diabetic retinopathy
clinical validation of the tiba medical ambulo 2400 abpm according to the iso 80601-2-30 standard in adults, adolescents, and children

Conditions: Hypertension

Summary: clinical validation of the tiba medical ambulo 2400 ambulatory blood pressure monitoring system according to the accuracy guidelines of the iso 80601-2-30 standard in adults, adolescents, and children.


Eligibility criteria:
inclusion criteria: * ages \> 3 years old exclusion criteria: * severe arrhythmia

Keywords: hypertension hypotension clinical validation blood pressure accuracy iso 81600 standard british hypertension society european society of hypertension international protocol
ureteroscopy with high-powered holmium:yag laser lithotripsy with and moses on or moses off

Conditions: Kidney Stone; Ureteral Stone

Summary: the purpose of this study is to compare moses 2.0 pulse modulation technology and the standard high powered holmium laser lithotripsy and how it will affect time in the operating room, time using the laser, laser energy, and stone free rates. currently moses 2.0 laser technology is fda approved and currently used in practice since 2021. no study to this date has compared moses 2.0 without pulse modulation laser technology to moses 2.0 with pulse modulation laser technology. the study will be including kidney and ureteral stones (a kidney stone located in the tube between the kidney and the bladder) that are 6mm and greater, but less than 20 mm in size undergoing ureteroscopic treatment. high powered lasers are used for "dusting". dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.

on the day of surgery, the treatment assigned to the patient will be determined by chance, like flipping a coin. neither the patient nor the study doctor will choose the treatment type. each patient will have an equal chance of being given either surgical treatment. one group will have stones treated with high powered laser dusting with moses 2.0 pulse modulation and the dust produced will pass spontaneously through the urine. the other group will have stones treated with standard of care high power laser fragmentation and the dust produced will pass spontaneously through the urine. the surgical procedure will not differ from the treatment a patient would receive if he/she were not in this study. 8 to 12 weeks after surgery, participants will undergo a standard of care renal bladder ultrasound (rbus) and kidney ureter bladder abdominal x-ray (kub) to evaluate for stones and hydronephrosis, which is swelling of the kidney due to build-up of urine. if there are abnormal findings on the rbus or kum at the 8 to 12 week follow-up, participants will be asked to return to the urology clinic and may have to repeat imaging to ensure participants did not develop a postoperative condition.

Eligibility criteria:
inclusion criteria: * undergoing ureteroscopy and laser lithotripsy * stone size ≥8 but \< 20 mm in the proximal ureter or kidney. multiple stones ≤4 are allowed. bilateral surgeries are allowed * willing to sign informed consent exclusion criteria: * staged surgery * nephrocalcinosis * participant is less than 18 years of age * inability to provide informed consent * members of vulnerable patient populations
clarithromycin as adjuvant to periodontal debridement

Conditions: Aggressive Periodontitis

Summary: to assess the periodontal clinical response and the possible adverse effects of the clarithromycin combined to periodontal mechanical therapy in the treatment of patients with generalized aggressive periodontitis.

to assess the periodontal clinical response and the possible adverse effects of the clarithromycin combined to periodontal mechanical therapy in the treatment of patients with generalized aggressive periodontitis.forty patients were select and randomly assigned into two groups: group clarithromycin with 20 subjects that received one-stage full-mouth ultrasonic debridement (fmud) associated with clarithromycin (500 mg - 12/12 hours) for 3 days; group placebo with 20 subjects that received fmud associated with placebo. probing depth (pd), gain in clinical attachment level (cal) and bleeding on probing (bop) were evaluated at baseline, 3 and 6 months post- operatively.

Eligibility criteria:
inclusion criteria: * diagnosis of generalized aggressive periodontitis * presence of ≥20 teeth * presence of ≥ 6 sites presenting probing depth (pd) ≥5mm with bleeding on probing (bop) and ≥2 sites with pd ≥7mm (including incisors and first molars, in addition to two other non-contiguous teeth between them) * good general health * \<35 years of age * agree to participate in the study and sign a written consent exclusion criteria: * pregnant or lactating * suffering from any other systemic disease (e.g. cardiovascular, diabetes, blood dyscrasias, immunodeficiency, etc) which could alter the course of periodontal disease * received antimicrobials in the previous 6 months * taking long-term anti-inflammatory drugs * received a course of periodontal treatment within the last 12 months * smoked

Keywords: clarithromycin periodontal debridement aggressive periodontitis
medical radiometer - rtm - 01 - res and its use in detecting hotspots in female breast

Conditions: Breast Cancer

Summary: medical radiometer depends on detecting the microwaves that radiates from deep structure hot objects in the body. when it comes to the breast, causes of deep structure hot spots are numerous, it can be inflammatory, hormonal or neoplastic. therefore, the primary objective of this study is to test the sensitivity of the medical radiometer in detecting the hot spots in the breast.

several pathological lesions and physiological changes can cause spot in the breast to show higher temperature than it should be. the causes can be: \[i\] physiological: during menarch, puberty, menstruation, lactation and after sexual intercourse. \[ii\] inflammatory: mastitis and breast abscess. \[iii\] endocrinal: any cause of increasing oestrogen, prolactin and/or thyroid hormones. \[iv\] neoplastic: the neo-vascularisation of the malignant tumors. radiometer is a machine that can detect through its sensitive probe the microwave that radiate from the deep structures in the body. the main aim of this study, first is to measure the sensitivity of the rtm in detecting the hot spots of different breast lesions. the second objective is to study the temperature patter of each disease trying to figure out a diagnostic code for the different lesions. the tertiary objective is to combine the echo-dobbler in studying the hot spots in the neoplastic lesions trying to figure out an accurate protocol to early detect the malignant hot spots.

Eligibility criteria:
inclusion criteria: * the perfect sample should be 2000 females or more. * 50 % already diagnosed breast cancer of any type * 30% normal thought to be healthy females. * 10% lactating * 10% different breast diseases exclusion criteria: * menstruating females.

Keywords: rtm female breast cancer
genicular nerve and intra-articular radiofrequency versus platelet rich plasma injection for knee osteoarthritis

Conditions: Chronic Knee Osteoarthritis

Summary: the social impact of degenerative diseases such as articular cartilage pathology and osteoarthritis (oa) is steadily increasing, because of the continued rise in the mean age of the active population. a variety of noninvasive solutions have been proposed for pain treatment, improvement in function and disability, and ultimately, modification of the course of severe cartilage lesions and oa, with variable success rates. intra articular and genicular nerves radiofrequency (rf) is a minimally invasive technique that usually aims at the neuropathic pain. one important mechanism for the chronic pain mediated by oa is peripheral sensitization, which increases the transmission of pain signals. through conduction block in pain-transmitting nerve fibers by thermal damage, rf could ease pain without destroying the antennal nerve. the role of growth factors (gfs) in chondral repair is now widely investigated in vitro and in vivo. platelet-rich plasma (prp) is a simple, low cost, and minimally invasive method that allows one to obtain from the blood a natural concentrate of autologous gfs.

the aim of this study is to compare the efficacy of intra articular platelet rich plasma (prp) injection versus combined ultrasound guided intra articular and genicular nerve pulsed radiofrequency on chronic knee pain in patients with knee osteoarthritis. the regeneration capacity of cartilage is limited because of its isolation from systemic regulation and its lack of vessels and nerve supply. osteoarthritis (oa) has a major impact on functioning and independence and ranks among the top 10 causes of disability worldwide

Eligibility criteria:
inclusion criteria: * patients experienced unilateral lesion with a history of chronic (≥4 months) * pain or swelling of the knee and imaging findings (radiography or magnetic resonance imaging \[mri\]) of degenerative changes of the joint * patients shall to be clinically unresponsive to conservative treatment modalities exclusion criteria: * diabetes * rheumatic diseases * coagulopathies * severe cardiovascular diseases * infections * immunosuppression * patients receiving anticoagulants * use of non-steroidal anti-inflammatory drugs in the 5 days before blood donation * hemoglobin concentration less than 10 g/dl * platelet count less than 150,000/cubic mm.
internet-based cbt for insomnia in chronic pain

Conditions: Chronic Insomnia; Chronic Pain

Summary: the main goal is to study the effect of therapist-guided internet-delivered cognitive behavioural therapy for insomni comorbid with chronic pain in a clinical sample.

both chronic pain and sleep disorders are prevalent and potentially very debilitating problem. the prevalence of insomnia in people with chronic pain seems to be about 50%, but figures up to 88% have been reported. cognitive behavioral therapy for insomnia (cbt-i) has been shown to be an effective treatment for both primary insomnia and co-morbid insomnia. cbt-i is a psychotherapeutic multicomponent treatment that seeks to influence the behaviors and cognitions which perpetuates the problem. usually, the treatment is 6-8 weeks long with one session a week, individually or in a small group setting. internet mediated cbt-i has been shown to be an effective alternative to more traditional cbt. how well internet mediated cbt-i work for individuals with insomnia and co-morbid chronic pain has however not previously been investigated. the aim of the project is to study the effects of internet mediated cognitive behavioral therapy for individuals with insomnia and co chronic benign pain. the aim is to compare the effect of internet-mediated cognitive behavioral therapy with a group that offered internet-based relaxation training. cbt-i comprises eight modules with evidence-based treatment components for insomnia (e.g. sleep restriction, stimulus control and cognitive techniques). the relaxation training comprises eight modules of applied muscular relaxation. hypothesis: patients suffering from both insomnia and chronic benign pain gets significantly better treatment outcome with respect to insomnia symptoms if they receive internet-based cognitive behavioral therapy compared to those receiving internet mediated relaxation training. primary outcome measure: the insomnia severity index (isi), a well-used, valid and reliable self-report scale, which has been shown possible to administer via internet.

Eligibility criteria:
inclusion criteria: * chronic insomnia chronic benign pain no or stable pharmacological treatment for insomnia and or pain exclusion criteria: * participation in pain management programme pregnancy shift work untreated medical or psychiatric disease or disorder that could be negatively affected by insomnia treatment

Keywords: cognitive behavioural therapy non-pharmacological treatment internet mediated
a study of pharmacokinetic comparison of two recombinant exendin-4 formulations in chinese healthy male subjects

Conditions: Type 2 Diabetes

Summary: evaluation of the pharmacokinetics and safety re-4 injection versus re-4 freeze-dried powder in healthy subjects.

the study design is an open-label randomized, single-dose, 2-way crossover bioequivalence study with a washout period of 7 days. during each session, the subjects will receive a subcutaneous single dose of re-4 (re-4 injection 10µg or re-4 freeze-dried powder 10µg) administered 30min prior to the start time of a standard breakfast.

Eligibility criteria:
inclusion criteria: * healthy male adult volunteers of 18-45 years old, who can be inserted needle. * body mass index (bmi) of 19 to 26 kg/m2, inclusive bmi = weight (kg)/\[height(m)\]2，during screening period body weight≥50 kg. * subjects are fully informed and voluntarily consent to participate in this study. exclusion criteria: * a positive result in hepatitis b surface antigen (hbsag), hepatitis b e antigen (hbeag), anti-hepatitis c virus (hcv) antibodies, a syphilis test, or an human immunodeficiency virus (hiv) test. * history or presence of neurological, cardiovascular, renal, hepatic, pancreatic,gastrointestinal, pulmonary, metabolic, or musculoskeletal diseases. * history or presence neurological disorder disease. * abnormal laboratory profiles, routine inspection, vitl signs and ecgs results with clinical significance. * participation in a clinical drug study 30 days prior to present study. * fpg≥6.1mmol/l or \<3.9mmol/l. * sbp\ 140mmhg; dbp\>90mmhg. * use of any other drugs,vitamine and mineral substance. * blood donation more than 200 ml blood within 3 months prior to the study. * smoker (\>5 cigarettes/day) or alcoholist (355 ml alcohol/day). * history or family history of hypoglycemia. * history of allergy or hypersensitivity. * subjects planning to give birth or donate sperm during the study or within 3 months after the study. * other unfavorable factors diagnosed by investigators.
a study to learn about the study medicine bosulif in adult patients with chronic myeloid leukemia(cml).

Conditions: Chronic Leukemia Myelogenous

Summary: the purpose of this study is to look at how safe and effective is bosulif in routine clinical practice. this study is seeking for participants who are: * adult patients who are just confirmed to have chronic myeloid leukemia (cml) defined in local product document (lpd). cml is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. lpd explains what a medicine's benefits and problems are. lpd also explains how to use the medicine correctly in korea. * willing to take part in the study after being informed about the study. all participants in this study will receive bosulif. all participants who have entered this study should meet the usual prescribing criteria for bosulif as per the lpd. the participants will be treated with bosulif under routine clinical practice in korea. the study will look at the experiences of people receiving the study medicine. this will help to see if the study medicine is safe and effective. in this study all treatment and checking of the patients will be done as per the study doctor. the study can be performed in korean health care centers where bosulif is prescribed to treat cml after the patients have agreed to take part in the study.


Eligibility criteria:
inclusion criteria: * adult patients newly-diagnosed chronic phase (cp) philadelphia chromosome-positive chronic myelogenous leukemia (ph+ cml) or cp, ap, bp ph+ cml with resistance or intolerance to prior therapy * evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. exclusion criteria: - patients to whom bosulif is contraindicated as per the local labeling- any patients (or a legally acceptable representative) who does not agree that pfizer and companies working with pfizer use his/her information

Keywords: philadelphia chromosome-positive (ph+)
magnetic resonance imaging studies of motor and thought processes

Conditions: Cerebrovascular Disorder; Healthy; Movement Disorder; Nervous System Disease; Spinal Cord Injury

Summary: magnetic resonance imaging (mri) is a diagnostic tool that creates high quality images of the human body without the use of x-ray (radiation). mri is especially useful when studying the brain, because it can provide information about certain brain functions. in addition, mri is much better than standard x-rays at showing areas of the brain close to the skull and detecting changes in the brain associated with neurological diseases. in this study researchers will use mri to gather information about the processes that control human movement and sensory processing. the purpose of the study is to investigate how the brain is activated when remembering, thinking, or recognizing objects. researchers would like to determine what happens to brain functions when patients have trouble remembering, thinking, or recognizing objects following the start of disorders in the brain and nervous system. in addition, this study will investigate the processes of motor control in healthy volunteers and patients with disease.

the main purpose of the studies presented in this protocol is to investigate the physiology of motor control in health as well as the pathophysiological modifications taking place during disease. patients and normal volunteers will be scanned at rest and during different tasks, either while making repetitive movements or undergoing sensory stimulation. these studies should provide new insight concerning the processes that control human movement and sensory processing. the studies described in this protocol will be conducted by systems operating on 1.5 tesla up to 4 tesla, including a system at 3 tesla which is going to be installed in near future.

Eligibility criteria:
patients with movement disorder and normal volunteers.

Keywords: movement disorders sensory processing stroke spinal cord injury blood flow blood volume cognitive function neurobehavioral deficits neurological disorders magnetic resonance imaging plasticity normal volunteer